Designing a Cholesterol Efflux Assay
The Requirement Most Often Missed
Efflux is cholesterol movement from a cell to an extracellular acceptor — lipid-poor apoA1, HDL particles, or cyclodextrin. Without a defined acceptor, cholesterol leaves the membrane and re-partitions into the medium and back, and the measurement reports a bidirectional exchange rather than an efflux capacity.
| Acceptor | Pathway | Typical use |
|---|---|---|
| Lipid-poor apoA1 | ABCA1 | ABCA1-specific efflux |
| HDL2/HDL3 | ABCG1, SR-B1 | Macrophage efflux capacity |
| Cyclodextrin (MβCD) | Non-specific, diffusion-based | Maximum extractable pool; not a transporter assay |
| Serum or lipoprotein-deficient serum | Multiple | Physiological context, but undefined |
Important distinction. Cyclodextrin efflux is fast, large and transporter-independent. It is useful as a normalisation reference for the labelled pool, but it is not a measure of ABCA1 function. Studies that use it as the primary efflux readout are measuring membrane accessibility, not transport.
Part 1 — Labelling and Equilibration
| Step | Detail | Why |
|---|---|---|
| Label | ³H-cholesterol, or a fluorescent analogue (NBD-cholesterol, 22-NBD) | ³H is the reference; fluorescent analogues differ in trafficking |
| Labelling duration | 24–48 h in serum-containing medium | Allows distribution into all pools |
| Equilibration | 12–24 h after labelling, before the assay | Label must reach the regulatory pool |
| Wash | Thorough, at 37 °C | Surface-bound label is not efflux |
| ACAT inhibition (optional) | To prevent esterification of the label | Otherwise label enters the ester pool and efflux is underestimated |
Caveat on short labelling. A label applied for two hours remains largely in the plasma membrane, and its efflux reports plasma membrane exchange rather than the intracellular pool that ABCA1 draws from. Short labelling is a common reason for detecting little ABCA1 effect.
Caveat on fluorescent analogues. NBD-cholesterol is handled differently from cholesterol in several respects, including esterification and membrane flip-flop. Relative comparisons within one experiment are reasonable; absolute comparisons with ³H data are not.
Part 2 — The Assay
| Parameter | Typical | Note |
|---|---|---|
| Acceptor concentration | 10–50 µg/mL apoA1; 25–50 µg/mL HDL | Titrate; saturation indicates a different limiting step |
| Incubation | 2–6 h | ABCA1-mediated efflux is measurable within 2 h |
| Temperature control | 4 °C arm | Distinguishes transport from diffusion and binding |
| Medium | Serum-free during efflux | Serum lipoproteins are competing acceptors |
| Measurement | Counts in medium versus cells | Report as a percentage of total label |
| Normalisation | To total label, then to a reference condition | Not to protein alone |
Readout note. The 4 °C arm is the cheapest control and the most informative: efflux that persists at 4 °C is largely diffusion or desorption, not transporter-mediated. Reporting it converts "efflux" into "active efflux".
Part 3 — Inducing and Testing ABCA1
| Manipulation | Effect | Confound |
|---|---|---|
| LXR agonist (TO901317, GW3965) | ABCA1 induction | Also induces lipogenesis and ABCG1 |
| cAMP analogue (macrophages) | ABCA1 induction | Broad effects |
| ABCA1 knockdown or knockout | Reduced efflux to apoA1 | Specific if validated |
| Liver X receptor knockout | Reduced basal efflux | Developmental compensation |
| Cholesterol loading | Increases ABCA1 post-translationally | Also loads other pools |
Important distinction. LXR activation increases efflux and also increases lipogenesis, so a change in efflux after LXR activation cannot be attributed to ABCA1 without a knockdown arm. The knockdown is the specificity control; the agonist is the physiological stimulus.
Part 4 — Interpreting the Result
| Observation | Supports | Does not support |
|---|---|---|
| Efflux to apoA1 rises with ABCA1 induction, falls with knockdown | ABCA1-mediated efflux changed | Total cholesterol changed |
| Efflux rises but free cholesterol is unchanged | Increased turnover of the free pool | Accumulation or depletion |
| Efflux falls and free cholesterol rises | Impaired removal | Toxicity |
| Efflux unchanged with cyclodextrin, changed with apoA1 | Transporter-specific effect | Membrane accessibility change |
| Both acceptors changed equally | Membrane pool changed | Transporter-specific effect |
The fifth row is the discriminating comparison: if efflux to cyclodextrin and to apoA1 change in parallel, the membrane pool changed rather than the transporter. Reporting both acceptors is the single most useful design feature.
Part 5 — Common Failures
- • No acceptor defined, so the measurement is release.
- • Serum present during efflux, supplying competing acceptors.
- • Short labelling, so only the plasma membrane pool is sampled.
- • No equilibration period.
- • 4 °C control omitted.
- • Cyclodextrin efflux reported as ABCA1 function.
- • LXR agonist effect attributed to ABCA1 without a knockdown.
- • Efflux normalised to protein, in a treatment that changes protein content.
- • Fluorescent analogue results compared directly with ³H results.
Part 6 — Where This Article Connects
Efflux is the removal arm of the cholesterol module described in the pillar, and it determines the free cholesterol fraction that the cholesterol article identifies as the toxic species. It connects to the phospholipid article through membrane composition, which changes acceptor accessibility, and to the droplet biology article, because esterified cholesterol can be stored and later hydrolysed.
If you need efflux measured with a defined acceptor and a transporter-specific control, we can scope the design with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
Efflux capacity, acceptor affinity and ABCA1 inducibility vary with cell type, loading history and membrane composition. The conditions here are starting points.
Efflux to an acceptor does not establish which transporter mediated it, and a change in efflux does not establish a change in total or free cholesterol.
Scientific interpretation and experimental design
- • An acceptor defines the assay. Otherwise it is release.
- • Equilibrate the label. Acute labelling samples the membrane only.
- • Include 4 °C. It separates active from passive.
- • Run two acceptors. Cyclodextrin versus apoA1 distinguishes pool from transporter.
- • Knockdown is the specificity control for any induction experiment.
- • Serum out during efflux.
Selected references for further reading
- • Rothblat GH, et al. Cell cholesterol efflux: integration of old and new observations provides new insights. Journal of Lipid Research. 1999;40:781–796.
- • Wang N, et al. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. PNAS. 2004;101:9774–9779.
- • Sankaranarayanan S, et al. A sensitive assay for ABCA1-mediated cholesterol efflux using BODIPY-cholesterol. Journal of Lipid Research. 2011;52:2332–2340.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »